drug
alpelisib
Marketedupdated 6mo agoby $NVS NOVARTIS AG
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying alpelisib
- phase2EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
- phase3Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
- phase3Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
- phase2Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum
- phase2Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
- phase3Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
- phase2A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
- phase3Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 18, 2027
62 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (22)
- Feb 17, 2037method-of-use (U-4359)US 11433059
- Feb 17, 2037method-of-use (U-4359)US 11433059
- Feb 17, 2037method-of-use (U-4359)US 11433059
- Feb 17, 2037method-of-use (U-4359)US 11433059
- Feb 17, 2037method-of-use (U-4288)US 12427141
- Feb 17, 2037method-of-use (U-4288)US 12427141
- Feb 17, 2037method-of-use (U-4288)US 12427141
- Feb 17, 2037method-of-use (U-4288)US 12427141
- Apr 29, 2033compositionUS 8227462
- Apr 29, 2033compositionUS 8227462
- Apr 29, 2033compositionUS 8227462
- Apr 29, 2033compositionUS 8227462
- Apr 29, 2033compositionUS 8227462
- Apr 29, 2033compositionUS 8227462
- Apr 29, 2033compositionUS 8227462
- Sep 10, 2029compositionUS 84762682.8y
- Sep 10, 2029compositionUS 84762682.8y
- Sep 10, 2029compositionUS 84762682.8y
- Sep 10, 2029compositionUS 84762682.8y
- Sep 10, 2029compositionUS 84762682.8y
- Sep 10, 2029compositionUS 84762682.8y
- Sep 10, 2029compositionUS 84762682.8y
FDA exclusivities (6)
- Apr 5, 2029ODE-396Orphan Drug (7y)2.4y
- Apr 5, 2029ODE-396Orphan Drug (7y)2.4y
- Apr 5, 2029ODE-396Orphan Drug (7y)2.4y
- Jan 18, 2027I-937Indication (3y)62d
- Jan 18, 2027I-937Indication (3y)62d
- Jan 18, 2027I-937Indication (3y)62d
News(4)
- Merck KGaA spinout iOnctura touts PI3K delta inhibitor in metastatic eye canceriOnctura’s PI3K delta inhibitor shows promise in phase 1 study in patients with mostly pre-treated metastatic melanoma.fiercebiotech · 1mo ago
- Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trialGedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.biopharma_dive · 5mo ago
- The OncFive: Top Oncology Articles for the Week of 5/3The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.onclive · 6mo ago
- Celcuity strengthens case for ASCO-spotlighted breast cancer drugThe new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.biopharma_dive · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that